cyrilzakka/clinical-trials huggingface dataset:
Estimation of Muscle Area and Thickness of Deep Cervical Muscle Contraction During Cervical and Limb Movements

The purpose of this study is to investigate the validity and reliability of measurement for cervical multifidus using ultrasonography, and to investigate cervical multifidus muscle function by the change pattern of multifidus thickness, and to compare the changes in muscle thickness among different resistance levels (rest, 25%, 50%, 75% and 100%) and different cervical levels (C4, C5 and C6).

Cervical multifidus has specific sensory and motion function. However, it was unclear about muscle architectural change of cervical multifidus during head retraction manoeuvre with progressive resistance. The validity and reliability of measuring cervical multifidus using ultrasonography hasn't been proven.

In the pilot study, thickness, width and area of multifidus were measured at C4, C5 and C6 were measured using MRI and ultrasonography. The limit of agreement and the regression analysis were used to compare the results of two modalities. Besides, muscle thickness was repeatedly measured during the static and head retraction manoeuvre using ultrasonography by the same rater on the same day; the CVw and CVb were used to investigate reliability. In the main study, multifidus architecture measured in twenty asymptomatic subjects (24.3±4.7 yo, 5 women and 15 men) during head retraction manoeuvre with progressive resistance and during relaxation using ultrasonography apparatus with 10MHz linear transducer. ANOVA with repeated measurement and post-hoc analysis were to investigate the difference among different cervical levels and resistance force levels.

The results of the pilot study showed that the limit of agreement was ±0.20 cm and the moderate level of correlation (R2 ranged in 0.42\~0.64) for muscle thickness measured between MRI and ultrasonography. For muscle thickness, the CVw values under static and under head retraction against maximum resistance were lower than 10%. In the main study, there was a curvilinear relationship between muscle thickness change and resistance, and the quadratic equations were the proper curves for estimation. There was significant difference of muscle thickness change within 50% of maximum retraction against resistance; and there was no significant difference among three cervical levels. It was suggested that muscle at C6 relaxed more slowly during the period from the beginning of relaxation.

In conclusion, the present study built a valid and reliable method for measuring continuous and dynamic changes of muscle thickness using ultrasonography. The results supported muscle function of cervical multifidus for segmental stability but not for force production.

Eligibility Criteria:
Inclusion Criteria:

* participants without posterior cervical pain within recent 3 months before entry the study

Exclusion Criteria:

* Posterior cervical pain
* Surgery over cervical spine
Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion

This is an observational registry, sponsored by Saint Luke's Hospital. This study is to be conducted according to DHHS Guidelines, applicable state regulations, and local IRB policies and procedures. The overall objective is to address current gaps in knowledge regarding CTO-PCI, as a prospective, multi-center, single-arm study of 1,000 participants.

* 1,000 participants will be enrolled into the OPEN CTO study.
* Study coordinators will screen both men and women over the age of 18 who are admitted for an elective CTO-PCI procedure.
* Study coordinators will be trained by the Coordinating Center at Saint Luke's Hospital of Kansas City.
* Participants will be screened for Eligibility, and Informed Consent will be obtained.
* Participants will also be asked to sign a Medical Records Release form, and a Billing Records Release form.
* Detailed procedural data will be obtained by the Study Coordinator and local Principal Investigator.
* Participants will undergo a Baseline interview.
* These data will be entered into the electronic data capture system, Velos, which has stringent protections and quality controls.
* Participants will have telephone follow-up interviews conducted by the centralized Follow-up Center at Saint Luke's Hospital.

Eligibility Criteria:
Inclusion Criteria:

* Subject is scheduled for a PCI procedure for at least one chronic total occlusion with TIMI antegrade flow of zero.
* Subject is ≥ 18 years of age at the time of consent.

Exclusion Criteria:

* The CTO segment is in a graft
* Female subjects with a positive quantitative or qualitative pregnancy test, in accordance with hospital policy.
* Non-English speaking
* Too hard of hearing to do follow-up by telephone.
* Previously enrolled in OPEN CTO Registry
* Currently a prisoner
* Dementia
* Subjects with no way contact by telephone for follow-up.
Preoperative vs. Postoperative Rectal Misoprostol in Cesarean Section

This prospective double-blind placebo-controlled randomized clinical trial will be conducted at Ain-Shams University Maternity Hospital from April 2017 till December 2017. Group 1 women, candidates for cesarean section, will receive preoperative rectal 400 microgram of misoprostol, and Group 2 women will receive postoperative rectal 400 microgram of misoprostol.

2017. 120 women candidate foe elective cesarean section will receive preoperative sublingual 400 microgram of misoprostol, and another 120 women will receive postoperative sublingual 400 microgram of misoprostol.


Eligibility Criteria:
Inclusion Criteria:

1. Patients candidate for cesarean section.
2. Full term pregnancies (GA 37- 42 Wks).
3. Age (18-40 yrs).
4. body mass index (BMI) (20-30(Kg/m2 .

Exclusion Criteia:

1. Contraindication to spinal anesthesia.
2. Blood dyscrasias.
3. Large fibroids.
4. Contraindications to prostaglandin therapy (e.g. history of severe bronchial asthma or allergy to misoprostol.
5. Emergency CS such as fetal distress
6. Extreme of BMI (\<20 or \>30 Kg/m2 ).
A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Mole

Hydatidiform mole is a common complication of pregnancy with an incidence of 1in 400 pregnancies in India. Although this is a benign condition , it is having the malignant potential too. A repeat curettage after evacuation of hydatidiform mole was generally advocated till 1990s. A thorough curettage at the time of initial evacuation was not performed because of larger size of uterus and risk of perforation. Subsequently a number of studies assessed the usefulness of repeat curettage and found it was unnecessary and not cost effective . However all these studies are retrospective in design and conducted in developed countries where hydatidiform mole is diagnosed earlier because of wider use of ultrasonography. Thus there is a need to perform a well designed prospective study to compare the effectiveness of single evacuation with double evacuation in treatment of hydatidiform mole for prevention of Gestational Trophoblastic Neoplasia.This study compares the effectiveness of single evacuation versus double evacuation for treatment of hydatidiform mole for prevention of gestational trophoblastic neoplasia .


Eligibility Criteria:
Inclusion Criteria:

* Ultrasound confirmed complete mole

Exclusion Criteria:

* Partial mole
* History of treatment for molar pregnancy like prior evacuation or chemotherapy
* Women requiring hysterectomy for treatment of H Mole
Effects of Erector Spinae Plane Block on Postoperative Pain Following Lumbar Fusion Surgery

The purpose of this study is to determine if the method for injecting local anesthesia affects patients' pain and opioid usage after surgery. The investigators will compare subcutaneous anesthesia, injections of anesthesia under the skin, to a method called erector spinae plane block (ESPB). An ESPB injection involves placing local anesthesia along the muscles and bones in the back, using a special type of x-ray called fluoroscopy for guidance. The Investigators will use patient reported outcomes (PROs) and track subjects' opioid usage to find out if there is a difference between ESPB and subcutaneous anesthesia. The investigators hypothesize that patients who get ESPB injections will use less opioids and report less pain after lumbar fusion surgery compared to patients who receive subcutaneous anesthesia injections.


Eligibility Criteria:
Inclusion Criteria:

* The individual has signed and dated a study specific informed consent form approved by the Institutional Review Board at UMMHC.
* The individual is at least 18 years of age.
* The individual is skeletally mature (over the age of 18).
* The patient is scheduled for a one or two level lumbar spinal fusion.

Exclusion Criteria:

* Patients unable to consent for themselves.
* Pregnant women.
* Non-English speaking subjects.
* Prisoners.
* Spinal fusion procedures for a diagnosis of fracture, tumor, and/or infection.
* Patients who have used opioids for more than 10 days in the month prior to their operation.
* Patients with a body mass index (BMI) of 35 or greater.
Efficacy of Ultrasound-Guided PRP Versus Corticosteroid Injection in Patients With Ulnar Neuropathy at Elbow

This study was be performed on 60 patients with ulnar neuropathy at elbow diagnosed clinically and by electrophysiology and/or ultrasonography selected from Physical medicine, Rheumatology \& Rehabilitation Department, Faculty of Medicine, Tanta University.

Patients were be randomly divided into 2 groups:

Group I: will undergo a single ultrasound-guided deep perineural injection with 3ml PRP at the thickest part of the ulnar nerve. PRP will be prepared by PRP method.

Group II: will undergo a single ultrasound-guided deep perineural injection with 1ml corticosteroid (triamcinolone acetonide, 40mg/mL) mixed with 1ml lidocaine hydrochloride.


Eligibility Criteria:
Inclusion Criteria:

* Patients with ulnar neuropathy at elbow diagnosed clinically and by electrophysiology and/or ultrasonography.

Exclusion Criteria:

1. Patients with severe ulnar neuropathy at elbow according to Gu's classification. 15
2. Brachial plexopathy, peripheral neuropathy, and cervical radiculopathy.
3. History of recent elbow trauma or operation.
4. Malignant neoplasm.
5. Pregnancy.
6. Bleeding Disorders.
7. Factors affecting nerve healing process e.g., tobacco use and systemic corticosteroid administration.
8. Contraindications for PRP injection:

   1. Significant renal or hepatic dysfunction.
   2. Critical thrombocytopenia.
   3. Hemodynamic instability.
   4. Septicemia.
   5. Local infection at the site of the procedure.
   6. Consistent use of nonsteroidal anti-inflammatory drugs within the last two weeks.
   7. Local injection at the suspected treatment site within the last month.
   8. Recent fever or illness.
   9. Hemoglobin level \<10 g/dL.
   10. Platelet dysfunction disorders.
Prognosis--A Game-Based Intervention to Improve STEM Skills

The purpose of this study is to evaluate a game-based intervention (Prognosis) designed to improve science, technology, engineering, and mathematics (STEM) skills among high school-aged students.

The purpose of this study is to evaluate the usability, feasibility, and acceptability of a game-based intervention (Prognosis) designed to improve science, technology, engineering, and mathematics (STEM) skills among high school-aged students. The research questions are as follows:

H1: Students will find Prognosis usable, feasible, and acceptable and recommend continued development and testing of Prognosis.

H2: After playing Prognosis, students will be able to perform basic quantitative data skills such as calculating incidence and prevalence.

H3: After playing Prognosis, students will be able to observe patterns in data at the neighborhood and city level.

H4: After playing Prognosis, students will be able to construct explanations and models describing the organization of systems in the game and how they contribute to health outcomes.

H5: After playing Prognosis, students will be able to formulate and test hypotheses for how to best coordinate various city systems and leverage finite resources to reach their target health goal.

Eligibility Criteria:
Inclusion Criteria:

* Enrolled in study site high school
* 9th or 10th grade at time of study

Exclusion Criteria:

* Students not in 9th and 10th grade
Alefacept in Kidney Transplant Recipients

Alefacept, also known as Amevive®, is a medication approved by the Food and Drug Administration (FDA) in the United States and other countries for the treatment of psoriasis, which is a chronic inflammatory immunological skin condition that can result in chronic dry, red patches that are covered in scales. Alefacept is approved by the FDA for the treatment of psoriasis but not as an anti-rejection medication in transplant patients. It is now being tested in new kidney transplant patients as a supplement to other approved anti-rejection drugs. Alefacept will be used as an investigational drug in this study.

The reason for this study is to test whether using Alefacept will inhibit T cells, known as memory cells, using a test named ELISPOT-IFN. In patients with psoriasis, Alefacept inhibits these memory cells. If memory cells specific to your donor can be inhibited by this drug, it might prevent rejection and promote acceptance of the transplanted kidney in a unique manner.


Eligibility Criteria:
Inclusion Criteria:

* Able and willing to sign informed consent
* Adult (\>18years) kidney-alone transplant recipient
* 6 months post-transplant
* Persistently positive donor-stimulated ELISPOT-IFN (≥30 spots/300K cells)-2 positive assays separated by at least one week
* Female subjects of child bearing potential must have a negative urine or serum pregnancy test within 7 days prior to enrollment and must agree to maintain effective birth control during the study

Exclusion Criteria:

* Baseline CD4 count \<250 cells/uL
* Acute rejection episode within the 3 months prior to enrollment
* Clinically overt infection within the 3 months prior to enrollment
* History of BK polyoma viremia
* Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV)
* Subject has a current malignancy or a history of malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully
* Any major illnesses/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study, or could preclude the evaluation of the subject's response
Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris

Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months. After a baseline visit, patient returns for a control visit after 3 and 6 months of treatment. One reference lesion is clinically evaluated with pictures.


Eligibility Criteria:
Inclusion Criteria:

* Active or stable vitiligo vulgaris
* lesions at head or neck + maximum 10% lesions at the rest of the body

Exclusion Criteria:

* Topica during last 2 weeks
* Photo(chemo)therapy during last 4 weeks
* Segmentary vitiligo
Nevanimibe HCl for the Treatment of Classic CAH

This is a multicenter, intra-subject dose-titration open-label study of nevanimibe hydrochloride (HCl) for the treatment of classic congenital adrenal hyperplasia (CAH). Following a Screening Period of approximately 2-14 weeks, eligible subjects will enter a Baseline Period of approximately 2-8 weeks and then a 16-week Treatment Period. It is anticipated that the overall duration of the study per subject will range from 24-42 weeks.


Eligibility Criteria:
Inclusion Criteria:

* Documented historical diagnosis of classic CAH due to 21-hydroxylase deficiency and/or historical documentation of elevated 17-OHP
* Chronic glucocorticoid replacement therapy for at least 6 consecutive months prior to screening
* Stable glucocorticoid and mineralocorticoid regimen for at least 4 weeks prior to screening and throughout the treatment period of the study

Exclusion Criteria:

* Nonclassic CAH
* Other causes of adrenal insufficiency
* HIV, hepatitis B, or hepatitis C
* AST or ALT \>2x ULN, bilirubin or serum creatinine \>1.5x ULN
Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)

The purpose of this study is to compare the effectiveness and safety of indacaterol with salmeterol /fluticasone propionate treatment in patients with moderate chronic obstructive pulmonary disease who, on entry to the study are being treated with salmeterol /fluticasone propionate.


Eligibility Criteria:
Inclusion Criteria:

* Patients with moderate COPD (Stage II)
* Able to perform spirometry assessments
* Current or ex-smokers
* On treatment with the fixed-dose combination of salmeterol 50 µg/fluticasone propionate 500 µg MDDPI b.i.d. for the treatment of COPD for ≥ 3 months directly preceding Visit 1.

Exclusion Criteria:

* Having had a COPD exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization in the past year.
* Having a history of, or current ECG abnormality
* Asthma

Other protocol-defined inclusion/exclusion criteria may apply.
Evaluation of Post-endodontic Pain After Root Canal Treatment With Two Rotary Systems : Mtwo & Safe-sider

Post-endodontic pain (PP) still is major problem for endodontic patients, analgesics are routinely prescribed. Incidence of PP is reported extensively, and reviewed. PP is a complicated multi factorial process and is affected by factors related to patients, to the tooth and to the skills and experience of the dentist and because of that, if the interrelation of these factors is not considered in a PP, study data might be confusing. Any study trying to evaluate the effect of a specific technique or new device in the incidence or characteristics of PP should control all the confounding factors that have been described to be involved in the tested outcome.

reports mention a variable prevalence of PP, ranging from 82.9 to 10.6%. These variations are because of the differences in study methods, and treatment procedures after root canal treatment, selection of patients or experience and skills of the dentists, vary when different studies are compared.

Many studies had confirmed that chemomechanical debridement of the root canal results in extrusion of dentinal chips, pulp tissue fragments, necrotic tissues, microorganisms, and root canal irrigants through the apical foramen. All preparation techniques and instruments, regardless of maintaining shorter working length of the apical terminus have reported to be related with extrusion of infected debris, and some of them extruded less material and others extruded more.

Periapical inflammation and postoperative flare-ups may result from apical extrusion of debris that is also referred to as the "worm" of necrotic debris A common outcome of the studies examining the amount of apically extruded debris was that the techniques involving a push-pull filing motion usually produce a greater mass of apical debris than those have rotational action Files which has reciprocating and in-and-out filing motion, may act as a piston, extruding more debris and irrigants. While the file with continuous rotation motion like a screw conveyor improving transportation of dentinal chips and debris coronally.

In this study, investigators compare post-endodontic pain between these two systems. Mtwo ( continuous rotation system) with safe-sider (reciprocating system). Therefore, the aim of this study is Evaluation of post-endodontic pain after root canal treatment with two rotary systems: Mtwo \& safe-sider


Eligibility Criteria:
Inclusion Criteria:

* Age range 20-50 years
* the systemically healthy
* first or second molar teeth require root canal therapy
* irreversible Pulpitis signed without the apical
* root canal curvature of less than 25 degrees, according to Schneider techniques

Exclusion Criteria:

* Root canal treatment,
* history of medication (antibiotics, NSAID, opiates) of the patient 12 hours before treatment ,
* pregnancy,
* complex anatomy,
* channels blocked in the x-ray plate,
* internal and external resorption,
* open apex teeth,
* periodontal disease,
* inflammation and abscesses,
* sinus tract,
* presence of radiographic lesions,
* tooth sensitivity to percussion,
* absence of occlusal contact .
Open Label Extension In Cancer Patients

To evaluate the safety and efficacy of anti-NGF AB in cancer patients with pain due to bone metastases who participated in the double-blind Study A4091003 and who wish to receive open-label therapy.


Eligibility Criteria:
Inclusion Criteria:

* Prostate cancer, breast cancer, renal cell carcinoma or multiple myeloma that has been diagnosed as having metastasized to bone;
* Karnofsky Performance Score ≥40% at Baseline;
* patients randomized and treated with intravenous study drug in double-blind Study A4091003.

Exclusion Criteria:

* Patient was withdrawn from Study A4091003 for an adverse event or serious adverse event;
* Occurrence of any adverse event or condition during Study A4091003 or since termination from that study that, in the opinion of the Investigator, would put the patient at increased safety risk or should exclude the subject from participating in the open-label extension Study A4091029.